Highlights 

  • Phase 2 BESTOW trial showed a favorable safety and tolerability profile for tegoprubart 
  • Data supports advancement into Phase 3 for kidney transplant rejection prevention 
  • Financing of USd 57.5 million strengthens liquidity for development programs 
  • Long-term extension and additional studies to inform 2026 milestones 
  • Q3 2025 ended with cash and investments of USD 93.4 million 

Eledon Pharmaceuticals (NASDAQ:ELDN) released its third quarter 2025 update, highlighting significant clinical, regulatory, and financial developments. Central to the announcement were the encouraging results from the Phase 2 BESTOW trial, which evaluated tegoprubart as a potential alternative to traditional immunosuppressive therapies in kidney transplantation. According to the data presented at the American Society of Nephrology’s Kidney Week 2025, tegoprubart demonstrated a favorable safety and tolerability profile, meaningfully reducing the metabolic, neurologic, and cardiovascular toxicities frequently associated with tacrolimus. 

Kidney function in the tegoprubart cohort showed supportive outcomes, with an estimated glomerular filtration rate of approximately 69 mL/min/1.73m² at twelve months for the 51 participants receiving the treatment.  

Business and Pipeline Milestones 

Beyond the progress in kidney transplantation, Eledon is advancing tegoprubart across multiple transplant settings, including islet cell transplantation and xenotransplantation. The company expects to enroll the final three participants with Type 1 diabetes in the ongoing investigator-led islet cell transplantation study by the end of 2025. During 2026, the company anticipates receiving guidance from the U.S. FDA on the design and requirements for Phase 3 trials in kidney transplantation and additional regulatory pathways involving other transplantation applications. 

Throughout 2026, Eledon plans to report long-term data from both Phase 1 and Phase 2 studies, including nine-patient data from the islet cell study.  

Financial Performance in Q3 2025 

As of September 30, 2025, Eledon reportedcash, cash equivalents,and short-terminvestmentsof USD 93.4 million, compared to USD 140.2 million at the end of 2024. The quarter included R&D expenses of USD 15.0 million and general and administrative expenses of USD 4.1 million. The net loss for the period was USD 17.5 million, compared to a net income of USD 77.0 million in the same quarter of 2024, which reflected a USD 96.4 million non-cash gain arising from changes in the fair value ofwarrantliabilities. 

Crucially, the company completed a public offering on November 13, 2025, generating USD 57.5 million in gross proceeds. This financing is expected to support the advancement of tegoprubart across multiple indications and reinforce operational plans through 2026. 

Conclusion 

Eledon Pharmaceuticals’ third quarter of 2025 underscores meaningful clinical progress supported by encouraging safety data for tegoprubart. With strengthened financial resources and multiple upcoming milestones, the company is positioned to advance its lead candidate through late-stage development. The next year will be pivotal as Eledon works toward Phase 3 initiation and expands its footprint in transplantation medicine.